Publikationsdatenbank

Adeno-associated virus-vectored influenza vaccine elicits neutralizing and Fcγ receptor-activating antibodies (2020)

Art

Zeitschriftenartikel / wissenschaftlicher Beitrag

Autoren

Demminger, Daniel E.

Walz, Lisa

Dietert, Kristina (WE 12)

Hoffmann, Helen

Planz, Oliver

Gruber, Achim D. (WE 12)

von Messling, Veronika

Wolff, Thorsten

Quelle

EMBO molecular medicine

Bandzählung: 12

Heftzählung: 5

Seiten: e10938

ISSN: 1757-4676

Sprache

Englisch

Verweise

URL (Volltext): https://www.embopress.org/doi/epdf/10.15252/emmm.201910938

DOI: 10.15252/emmm.201910938

Pubmed: 32163240

Kontakt

Institut für Tierpathologie

Robert-von-Ostertag-Str. 15
14163 Berlin
+49 30 838 62450
pathologie@vetmed.fu-berlin.de

Abstract / Zusammenfassung

The current seasonal inactivated influenza vaccine protects only against a narrow range of virus strains as it triggers a dominant antibody response toward the hypervariable hemagglutinin (HA) head region. The discovery of rare broadly protective antibodies against conserved regions in influenza virus proteins has propelled research on distinct antigens and delivery methods to efficiently induce broad immunity toward drifted or shifted virus strains. Here, we report that adeno-associated virus (AAV) vectors expressing influenza virus HA or chimeric HA protected mice against homologous and heterologous virus challenges. Unexpectedly, immunization even with wild-type HA induced antibodies recognizing the HA-stalk and activating FcγR-dependent responses indicating that AAV-vectored expression balances HA head- and HA stalk-specific humoral responses. Immunization with AAV-HA partially protected also ferrets against a harsh virus challenge. Results from this study provide a rationale for further clinical development of AAV vectors as influenza vaccine platform, which could benefit from their approved use in human gene therapy.